Skip to content


Praluent (alirocumab) is an antibody pharmaceutical. Alirocumab was first approved as Praluent on 2015-07-24. It is used to treat atherosclerosis and hypercholesterolemia in the USA. It has been approved in Europe to treat dyslipidemias. The pharmaceutical is active against proprotein convertase subtilisin/kexin type 9.
Trade Name Praluent
Common Name Alirocumab
Indication atherosclerosis, dyslipidemias, hypercholesterolemia
Drug Class Monoclonal antibodies: fully human, cardiovascular indications
Get full access now